Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial

Robert S. Brown, Lino Rodrigues, Vladimir Chulanov, +18

Journal of Hepatology

Differential MicroRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer

Ziad Kanaan, N. Shesh, M. Robert Eichenberger, +9

Human Mutation

MedicineImmunologyColorectal CancerPathologyTp53 Pathway +10

Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria

Massimo De Giorgio, Stefano Vezzoli, Eric Cohen, +10

Liver Transplantation

Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma

Laurie Gashin, Elliot B. Tapper, Atinuke Babalola, +4

HPB

Multidisciplinary Tumour ConferenceHepatologyHealth PolicyCancer EpidemiologyMedicine +9

Deep vein thrombosis outcome and the level of oral anticoagulation therapy

Joseph A. Caprini, Juan I. Arcelus, José J. Reyna, +4

Journal of Vascular Surgery

ThrombosisVenous ThrombosisCardiovascular DiseaseVenous Disease TreatmentHematology +7

Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative

Eric Cohen, Meenal Patwardhan, Ritu Raheja, +11

Drug Safety

Efficacy and safety results of patients with <scp>HCV</scp> genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (<scp>QUARTZ II</scp>‐<scp>III</scp>)

Stephen D. Shafran, Douglas W. Shaw, Mariem Charafeddine, +8

Journal of Viral Hepatitis

[Thrombophilias associated with cerebral venous thrombosis].

Eric Schlück, G. Rodier, F Derouiche, +4

PubMed

IDDF2019-ABS-0210 Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1–6 infection and compensated cirrhosis: the EXPEDITION-8 study

Robert S. Brown, C. Hézode, Stanley Wang, +12

Iddf2019-abs-0210 Preliminary EfficacyAntiviral DrugAutoimmune Liver DiseaseHepatic DisordersViral Hepatitis +16